iGlarLixi CGM study in Chinese T2D individuals after OADs

Trial Identifier:	LPS18034
Sponsor:	Sanofi
Start Date:	December 2024
Primary Completion Date:	September 2026
Study Completion Date:	September 2026
Condition:	Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Beijing, China, 100730

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.